Economic implications of current age-related macular degeneration treatments. [electronic resource]
Producer: 20090320Description: 481-7 p. digitalISSN:- 1549-4713
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- economics
- Antibodies, Monoclonal -- economics
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Combined Modality Therapy
- Cost-Benefit Analysis
- Drug Therapy, Combination
- Glucocorticoids -- economics
- Health Care Costs
- Humans
- Macular Degeneration -- economics
- Models, Economic
- Photochemotherapy -- economics
- Ranibizumab
- Triamcinolone Acetonide -- economics
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Vision Disorders -- economics
- Visual Acuity
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.